Ibrutinib: Indication of added benefit in one of three therapeutic indications
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since ...
May 2, 2016
0
2